Prevalence of antibodies to vimentin/cardiolipin complex
| Autoantibodies to vimentin/cardiolipin complex . | SN-APS . | APS . | SLE . | RA . | Thrombosis . | Healthy subjects . |
|---|---|---|---|---|---|---|
| Antivimentin/cardiolipin IgG | 16/29 (55.2) | 37/40 (92.4) | 13/30 (43.3) | 5/30 (16.6) | 2/30 (6.6) | 0/32 (0) |
| Antivimentin/cardiolipin IgM | 11/29 (37.9) | 32/40 (80.0) | 13/30 (43.3) | 5/30 (16.6) | 0/30 (0) | 0/32 (0) |
| Autoantibodies to vimentin/cardiolipin complex . | SN-APS . | APS . | SLE . | RA . | Thrombosis . | Healthy subjects . |
|---|---|---|---|---|---|---|
| Antivimentin/cardiolipin IgG | 16/29 (55.2) | 37/40 (92.4) | 13/30 (43.3) | 5/30 (16.6) | 2/30 (6.6) | 0/32 (0) |
| Antivimentin/cardiolipin IgM | 11/29 (37.9) | 32/40 (80.0) | 13/30 (43.3) | 5/30 (16.6) | 0/30 (0) | 0/32 (0) |
Values are presented as n (%).
APS indicates antiphospholipid syndrome; IgG, immunoglobulin G; IgM, immunoglobulin M; RA, rheumatoid arthritis, SLE, systemic lupus erythematosus; and SN-APS, seronegative antiphospholipid syndrome.